Dr. Sebastian Beyer, LL.M. (Auckland)

Formycon

Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.

Hauck & Aufhäuser

A Taylor Wessing team led by Frankfurt-based partners Lars-Gerrit Lüßmann and Ulrich Reers advised Hauck & Aufhäuser Investment Banking and Polish universal bank mBank in their role as exchange trustee and settlement agent on the voluntary public takeover/exchange offer by Frankfurt-listed Vita 34 AG, Leipzig, to the shareholders of Warsaw-listed stem cell bank Polski Bank Komórek Macierzystych S.A, Warsaw (PBKM). The transaction is the first cross-border exchange offer for a Polish listed company to date.

Eckert & Ziegler Strahlen- und Medizintechnik AG on its public takeover of the Belgian company Eckert & Ziegler BEBIG SA

Eckert & Ziegler Strahlen- und Medizintechnik AG, a German FSE stock listed company on all aspects of a cross-border merger. Eckert & Ziegler Strahlen- und Medizintechnik AG, one of the world's largest suppliers of isotope technology components for radiation therapy and nuclear medicine with headquarters in Berlin, as absorbing entity merged with the Belgian Eckert & Ziegler BEBIG SA, which was listed on the Euronext Brussels stock exchange. The transaction is a rare example of cross-border mergers of two listed companies on the basis of the European harmonized requirements of the EU Company Directive (EU) 2017/1132.